# EDGAR Filing Document

**Accession Number:** 0001703647
**File Stem:** 0000000000-26-002740
**Filing Date:** 2026-3
**Character Count:** 2354
**Document Hash:** e1960b3cf86aa4a9becf042976cca6b4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-002740.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0000000000-26-002740

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260318

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Korro Bio, Inc.
- **CENTRAL INDEX KEY:** 0001703647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472324450
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-294298

**BUSINESS ADDRESS:**
- **STREET 1:** 60 FIRST STREET
- **STREET 2:** 2ND FLOOR, SUITE 250
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** 617-468-1999

**MAIL ADDRESS:**
- **STREET 1:** 60 FIRST STREET
- **STREET 2:** 2ND FLOOR, SUITE 250
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Frequency Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20170412
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-106378

## Text-Extract

```

                                                           March 18, 2026

Ram Aiyar
President, Chief Executive Officer and interim Chief Financial Officer
Korro Bio, Inc.
60 First Street, 2nd Floor, Suite 250
Cambridge, MA 02141

        Re: Korro Bio, Inc.
            Registration Statement on Form S-3
            Filed March 13, 2026
            File No. 333-294298
Dear Ram Aiyar:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tim Buchmiller at 202-551-3635 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Marianne Sarrazin, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._